AI news impact · China A-shares

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A (301096) news impact

On 2026-11-12 Wave Radar's AI rated the news on Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A as neutral (impact score +25%).

Baicheng Medical reported Q1-Q3 2026 total revenue of 450 million yuan and appeared on ChiNext margin balance increase rankings.

Direction
Neutral
Impact score
+25%
Confidence
75%
Headlines read
2
Date
2026-11-12
Open 301096 news in Wave Radar

AI assessment

Steady revenue of 450 million yuan reflects operational stability, accompanied by mild margin buying interest to support sentiment.

Sector impact

Neutral to minimal impact on the broader CRO and pharmaceutical R&D sector.

Headlines the AI read

Rating history

One rating per trading day the stock was covered.

More on Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. Class A

301096 valuation

How the rating works

After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.